TriangleHEALTH PROFESSIONAL · SOURCE READING
Targeted therapy (imatinib)
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
When surgical resection cannot be accomplished or the tumor is recurrent, treatment with imatinib (a tyrosine kinase inhibitor) has been effective in adult patients.[48-50]
Evidence (imatinib):
A systematic review of nine studies examined 152 adult patients with histologically proven dermatofibrosarcoma protuberans who were treated with imatinib.[51]
Source links and citations
A systematic review of nine studies examined 152 adult patients with histologically proven dermatofibrosarcoma protuberans who were treated with imatinib.[51]
The study demonstrated a complete response rate of 5.2%, a partial response rate of 55.2%, and a stable disease rate of 27.6%.
A systematic review of nine studies examined 152 adult patients with histologically proven dermatofibrosarcoma protuberans who were treated with imatinib.[51]
There were no differences in the response rates based on imatinib dosing of either 400 mg or 800 mg per day.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice